http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2616533-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ca24b9c43b9ff3cde2c5267901d3a22e |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 |
| filingDate | 2016-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99144a7d669a1d29ddc334909bc916bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3227cab8c04a080dc0726b437b0dad0b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_163c29e35bf154b366079757c5085d88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbd086127bdbe6b1e6f7640233e30db9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00ea332aea1998059c82b501cbee169a |
| publicationDate | 2017-04-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2616533-C1 |
| titleOfInvention | Method for everolimus therapy efficiency prediction for patients with metastatic renal cancer |
| abstract | FIELD: medicine. n SUBSTANCE: phospho-m-TOR is determined, and HIF-1 hypoxia induced factor,α VEGF vascular endothelial growth factor and its VEGFR2 receptor are determined additionally at the pre-operative treatment stage. At HIF-1α, VEGF, VEGFR2 values in the well of 16.2 AU/mg of protein in the well; 100.5 and 82.2 pg/mg of protein, respectively, as well as phospho-m-TOR levle less than 5.5 pg/mg of protein, high efficiency of everolimus therapy is predicted. At HIF-1α, VEGF, VEGFR2 values less than 16.2 AU/mg of protein in the well, 100.5 and 82.2 pg/mg of protein, respectively, and phospho-m-TOR level more than 5.5 pg/mg of protein, low efficiency of everolimus therapy is predicted. n EFFECT: method provides high accuracy of everolimus therapy efficiency prediction, which, in turn, allows to select the appropriate therapy. n 3 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2750026-C1 |
| priorityDate | 2016-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.